D. Boral Capital Begins Coverage on Plus Therapeutics (NASDAQ:PSTV)

Equities researchers at D. Boral Capital started coverage on shares of Plus Therapeutics (NASDAQ:PSTV) in a research note issued to investors on Monday, Marketbeat.com reports. The brokerage set a “buy” rating and a $9.00 price target on the stock.

Other equities research analysts have also issued research reports about the stock. HC Wainwright reissued a “buy” rating and issued a $8.00 price target on shares of Plus Therapeutics in a report on Tuesday, November 26th. Ascendiant Capital Markets dropped their target price on shares of Plus Therapeutics from $20.00 to $19.00 and set a “buy” rating for the company in a report on Monday, December 9th.

Plus Therapeutics Stock Performance

NASDAQ:PSTV opened at $0.68 on Monday. Plus Therapeutics has a fifty-two week low of $0.24 and a fifty-two week high of $2.67. The business has a 50 day moving average price of $1.13 and a 200-day moving average price of $1.26. The firm has a market cap of $4.00 million, a PE ratio of -0.27 and a beta of 0.73.

Plus Therapeutics Company Profile

Plus Therapeutics, Inc, a clinical-stage pharmaceutical company, focuses on the development, manufacture, and commercialization of treatments for patients with cancer. Its lead radiotherapeutic drug candidate is rhenium (186Re) obisbemeda, a patented radiotherapy that targets central nervous system cancers and other cancers, including recurrent glioblastoma, leptomeningeal metastases, and pediatric brain cancers.